BRPI0511196A - polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição - Google Patents

polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição

Info

Publication number
BRPI0511196A
BRPI0511196A BRPI0511196-0A BRPI0511196A BRPI0511196A BR PI0511196 A BRPI0511196 A BR PI0511196A BR PI0511196 A BRPI0511196 A BR PI0511196A BR PI0511196 A BRPI0511196 A BR PI0511196A
Authority
BR
Brazil
Prior art keywords
conjugate
polypeptide
virus
composition
hiv
Prior art date
Application number
BRPI0511196-0A
Other languages
English (en)
Inventor
Phillip A Patten
Sridhar Viswanathan
Torben Lauesgaard Nissen
Anne Vogt
Harald Kropshofer
Ralf Schumacher
Stephan Fischer
Stefan Seeber
Adelbert Grossmann
Friederike Hesse
Andreas Schaubmar
Roberto Falkenstein
Hans Koll
Markus Dembowski
Original Assignee
Maxygen Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Hoffmann La Roche filed Critical Maxygen Inc
Publication of BRPI0511196A publication Critical patent/BRPI0511196A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

POLIPEPTìDEO ISOLADO OU RECOMBINANTE, CONJUGADO, COMPOSIçãO, CéLULA HOSPEDEIRA, VETOR, MéTODOS PARA PREPARAR UM POLIPEPTìDEO, PARA PREPARAR UM CONJUGADO, PARA REDUZIR O NúMERO DE CóPIAS DE UM VìRUS EM CéLULAS INFECTADAS COM O VìRUS, PARA REDUZIR O NìVEL DE RNA HCV, DNA HBV E RNA HIV NO SORO DE UM PACIENTE INFECTADO COM HCV, HBV E HIV, E, USO DO POLIPEPTìDEO, DO CONJUGADO OU DA COMPOSIçãO. A presente invenção fornece polipeptídeos e conjugados de interferon-alfa e ácidos nucleicos que codificam os polipeptídeos. A invenção também inclui composições que compreendem esses polipeptídeos, conjugados e ácidos nucleicos; células contendo ou expressando os polipeptídeos, conjugados e ácidos nucleicos; métodos de fabricação dos polipeptídeos, conjugados e ácidos nucleicos; e métodos de uso dos polipeptídeos, conjugados e ácidos nucleicos.
BRPI0511196-0A 2004-05-19 2005-05-18 polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição BRPI0511196A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19
PCT/US2005/017471 WO2005113592A2 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
BRPI0511196A true BRPI0511196A (pt) 2007-12-04

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511196-0A BRPI0511196A (pt) 2004-05-19 2005-05-18 polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição

Country Status (14)

Country Link
US (9) US7318918B2 (pt)
EP (1) EP1753779A2 (pt)
JP (1) JP2008507298A (pt)
CN (1) CN101115769A (pt)
AR (1) AR049177A1 (pt)
AU (1) AU2005245918A1 (pt)
BR (1) BRPI0511196A (pt)
CA (1) CA2566247A1 (pt)
IL (1) IL178470A0 (pt)
MX (1) MXPA06013412A (pt)
NO (1) NO20065084L (pt)
RU (1) RU2006145020A (pt)
TW (1) TW200611910A (pt)
WO (1) WO2005113592A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
CA2360011A1 (en) 1999-01-05 2000-07-13 Trustees Of Boston University Ordered gene assembly
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
KR20070038462A (ko) * 2004-05-12 2007-04-10 퓨전원 인코포레이티드 향상된 접속 인식 시스템
CA2590245A1 (en) 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
CA2597317C (en) * 2005-03-09 2018-01-02 Superlab Far East Limited Uses of recombinant super-compound interferons
JP2008545393A (ja) 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド 進歩したインターフェロンαポリペプチド
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080014616A1 (en) * 2006-07-11 2008-01-17 Kevin Jarrell Methods of introducing targeted diversity into nucleic acid molecules
JPWO2008013082A1 (ja) * 2006-07-25 2009-12-17 株式会社ガルファーマ ガレクチン９−ポリマーコンジュゲート
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
EP2195338B1 (en) * 2007-10-01 2013-12-25 Pharmaessentia Corp. N-terminal modified interferon-alpha
KR20100103595A (ko) * 2008-01-18 2010-09-27 에프. 호프만-라 로슈 아게 비-글라이코실화된 단백질의 정제
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
AR074357A1 (es) * 2008-11-17 2011-01-12 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
BR112013031040A2 (pt) 2011-06-02 2016-11-29 Hanmi Science Co Ltd multímero insulina-polímero não peptidil e método para a produção dos mesmos
WO2013003555A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
CN108883180B (zh) * 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
WO2021150674A1 (en) * 2020-01-24 2021-07-29 Alkermes, Inc. Methods of purification

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
IT1167610B (it) 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
US4885166A (en) * 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
WO1992006707A1 (en) 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6007805A (en) 1994-03-07 1999-12-28 Imperial College Of Science And Technology Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
BR0010725A (pt) 1999-05-19 2002-02-19 Lexigen Pharm Corp Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
WO2001025438A2 (en) 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
KR20020065517A (ko) * 1999-11-12 2002-08-13 맥시겐 홀딩스 리미티드 인터페론 감마 접합체
CA2408851C (en) 2000-05-16 2011-07-12 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
JP4279258B2 (ja) * 2002-11-15 2009-06-17 エフ．ホフマン−ラ ロシュ アーゲー ＰＥＧ ＩＦＮアルファ２ａの位置異性体
RU2005118998A (ru) * 2002-11-18 2006-01-27 Максиджен, Инк. (Us) Полипептиды и конъюгаты альфа-интерферона

Also Published As

Publication number Publication date
US20080171363A1 (en) 2008-07-17
NO20065084L (no) 2006-12-01
WO2005113592A2 (en) 2005-12-01
US20070025966A1 (en) 2007-02-01
JP2008507298A (ja) 2008-03-13
US20080076710A1 (en) 2008-03-27
US20070225204A1 (en) 2007-09-27
US7541163B2 (en) 2009-06-02
EP1753779A2 (en) 2007-02-21
MXPA06013412A (es) 2007-01-23
US7531324B2 (en) 2009-05-12
AR049177A1 (es) 2006-07-05
US20070020734A1 (en) 2007-01-25
RU2006145020A (ru) 2008-06-27
US20050266465A1 (en) 2005-12-01
US20070020235A1 (en) 2007-01-25
US7537755B2 (en) 2009-05-26
AU2005245918A1 (en) 2005-12-01
WO2005113592A3 (en) 2006-04-06
IL178470A0 (en) 2007-02-11
US7541436B2 (en) 2009-06-02
US7318918B2 (en) 2008-01-15
US7531630B2 (en) 2009-05-12
TW200611910A (en) 2006-04-16
CA2566247A1 (en) 2005-12-01
CN101115769A (zh) 2008-01-30
US20070225205A1 (en) 2007-09-27
US20080031853A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
BRPI0511196A (pt) polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
Chaturvedi et al. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma
Krieger et al. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations
Ray et al. Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity
Zhang et al. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant
Andrés et al. African swine fever virus polyproteins pp220 and pp62 assemble into the core shell
Vivekanandan et al. Hepatitis B virus replication induces methylation of both host and viral DNA
Neuman et al. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth
Asabe et al. The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation
Kolupaeva et al. An enzymatic footprinting analysis of the interaction of 40S ribosomal subunits with the internal ribosomal entry site of hepatitis C virus
Zhou et al. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
Tavis et al. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, ɛ
Huang et al. Alphacoronavirus transmissible gastroenteritis virus nsp1 protein suppresses protein translation in mammalian cells and in cell-free HeLa cell extracts but not in rabbit reticulocyte lysate
Fan et al. Specific in vitro association between the hepatitis C viral genome and core protein
SI2338508T1 (en) The recombinant chimeric dengue rENEN3 / 4delta 30 (ME), rDEN2 / 4delta30 (ME), or rDEN1 / 4delta30 (ME) dengue rDEN3 / 4delta30 (ME), containing deletion 30 of nucleotides (delta30) in part 3 of the untranslated genome dengue type 4, wherein deletion 30 nucleotides corresponds to the structure of the stem-loop TL2
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
BR0016145A (pt) Clones infecciosos
Glass et al. Identification of a trans-acting activity from liver that stimulates hepatitis A virus translation in vitro
Lang et al. Immunotherapy for HCV infection: next steps
Jarczak et al. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons
Kim et al. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein
Macejak et al. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA
Mirazimi et al. ATP is required for correct folding and disulfide bond formation of rotavirus VP7
BRPI0209416A2 (pt) Novos vetores de expressão e uso dos mesmos
Ackrill et al. Nuclear proteins binding to an enhancer element of the major histocompatibility class I promoter: differences between highly oncogenic and nononcogenic adenovirus-transformed rat cells

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]